[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355060-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355060-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","from-mechanisms-to-therapy-the-role-of-tertiary-lymphoid-structures-in-bladder-cancer","From mechanisms to therapy - the role of tertiary lymphoid structures in bladder cancer","","Tertiary lymphoid structures (TLS) are ectopic lymphoid tissues formed within the tumor microenvironment (TME), where they support anti-tumor immunity. This review details TLS presence in bladder cancer, including induction mechanisms, functional roles, and links to clinical prognosis and emerging therapeutic value. Evidence indicates that higher TLS density, especially in mature TLS, associates with longer survival and better immunotherapy response. TLS formation is driven by chemokines, cytokines, and immune cell programs that create niches for T/B cell activation, expansion, and effector function, while translation challenges remain.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/from-mechanisms-to-therapy-the-role-of-tertiary-lymphoid-structures-in-bladder-cancer/355060/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/from-mechanisms-to-therapy-the-role-of-tertiary-lymphoid-structures-in-bladder-cancer/355060.png","ImageObject",300,407,{"name":42,"@type":43},"Noah","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are tertiary lymphoid structures (TLS) and where do they form in bladder cancer?","Question",{"text":63,"@type":64},"TLS are ectopic lymphoid tissues that form within the tumor microenvironment (TME) of bladder cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does TLS presence relate to patient outcomes and immunotherapy response?",{"text":68,"@type":64},"Higher TLS density, particularly in mature TLS, is associated with prolonged survival and improved response to immunotherapy, especially immune checkpoint inhibitors.",{"name":70,"@type":61,"acceptedAnswer":71},"What drives TLS formation and how do they contribute to anti-tumor immunity?",{"text":72,"@type":64},"TLS formation is driven by a network of chemokines, cytokines, and specific immune cells. They provide a niche that supports activation, clonal expansion, and effector functions of resident T and B cells.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355060,1790142077,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":118,"preview_page_count":33,"preview_urls":145},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","Yang et al. World Journal of Surgical Oncology (2026) 24:75  \n[https://doi.org/10.1186/s12957-026-04196-8](https://doi.org/10.1186/s12957-026-04196-8)  \nWorld Journal of Surgical Oncology  \nREVIEW Open Access  \nFrom mechanisms to therapy: the role of tertiary lymphoid structures in bladder cancer  \nJinshan Yang1, Xinxin Li1, Hao Xie1, Jiahao Guo1, Jiahui Wang2* and Chunhua Lin 1*  \nAbstract  \nTertiary lymphoid structures (TLS) are ectopic lymphoid tissues that form within the tumor microenvironment (TME) and play a crucial role in anti-tumor immunity. In recent years, their presence, formation mechanisms, and functional significance in bladder cancer have attracted considerable attention. This review comprehensively examines the mechanisms underlying TLS induction in bladder cancer, their role in mediating anti-tumor immunity, their correlation with favorable clinical prognosis, and their emerging potential as therapeutic targets. Current evidence suggests that high TLS density, particularly in mature forms, is associated with prolonged patient survival and improved response to immunotherapy. TLS formation is driven by a complex network of chemokines, cytokines, and specific immune cells. By providing a structured niche for the activation, clonal expansion, and effector functions of resident T/B cells, TLS exert potent anti-tumor effects. Therefore, strategies aimed at inducing or enhancing functional TLS represent a promising frontier in bladder cancer immunotherapy, although several challenges remain for successful clinical translation.  \nKeywords Tertiary lymphoid structures, Bladder cancer, Tumor microenvironment, Anti-tumor immunity, Immunotherapy, Mechanisms  \nIntroduction  \nBladder cancer is a highly prevalent malignant tumor of the urinary system globally [1]. According to recent epidemiological statistics, bladder cancer ranks as the tenth most common cancer worldwide, with approximately 573,000 new cases and 212,000 deaths reported in 2020 [2]. Its incidence shows marked sex differences,  \n*Correspondence:  \nJiahui Wang [jiahui.wang@qdu.edu.cn](jiahui.wang@qdu.edu.cn)[ ](jiahui.wang@qdu.edu.cn)Chunhua Lin [chunhua.lin@qdu.edu.cn](chunhua.lin@qdu.edu.cn)  \n1Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai 264000, Shandong, China  \n2Central Laboratory, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai 264000, Shandong, China  \nbeing about four times higher in men than in women, and is strongly associated with aging, with most cases occurring in individuals over 65 years of age [2, 3]. Cigarette smoking remains the most significant risk factor, accounting for 50–65% of cases in men and 20–30% in women, followed by occupational exposure to aromatic amines and chronic bladder irritation [4]. These epidemiological characteristics underscore the global health burden posed by bladder cancer and highlight the urgent need for more effective therapeutic strategies. Although immune checkpoint inhibitors (ICIs) have undeniably transformed the treatment landscape for advanced bladder cancer, offering new therapeutic options and improving survival outcomes, the overall response rates remain suboptimal. However, the field continues to evolve, with ongoing research aimed at refining patient selection,  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indica","cbCaiqQAkZOwavuO","https://ap.wps.com/l/cbCaiqQAkZOwavuO","pdf",1038364,"English","# Introduction\n# Mechanism of TLS formation in bladder cancer microenvironment\n## Initiation phase: persistent inflammatory stimuli and APC ac","[{\"question\":\"What are tertiary lymphoid structures (TLS) and where do they form in bladder cancer?\",\"answer\":\"TLS are ectopic lymphoid tissues that form within the tumor microenvironment (TME) of bladder cancer.\"},{\"question\":\"How does TLS presence relate to patient outcomes and immunotherapy response?\",\"answer\":\"Higher TLS density, particularly in mature TLS, is associated with prolonged survival and improved response to immunotherapy, especially immune checkpoint inhibitors.\"},{\"question\":\"What drives TLS formation and how do they contribute to anti-tumor immunity?\",\"answer\":\"TLS formation is driven by a network of chemokines, cytokines, and specific immune cells. They provide a niche that supports activation, clonal expansion, and effector functions of resident T and B cells.\"}]","From mechanisms to therapy - the role of tertiary lymphoid structures in bladder cancer | PDF",1790115667,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a065524c2b2f42227416062bf240a666.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa36f4b5ef0b705ff102c5ba96776bd2.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b41ea0acbeb47bcc948cbd7ec3e580f8.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58cbf520073ab90acd7711122ba67bd5.webp",980,1306]